跳至主要内容
临床试验/NCT00063102
NCT00063102已完成2 期

A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens

Abbott13 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2002年11月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Abbott
入组人数
40
试验地点
13
主要终点
Objective Response Rate in subjects with Breast cancer

研究概览

简要总结

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Stage IIIB or IV breast cancer.
  • Recurrent tumor after or while on taxane therapy (taxol or taxotere).
  • Able to tolerate normal activities of daily living.
  • Adequate bone marrow, kidney and liver function.

排除标准

  • Pregnant or breast feeding.
  • No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the start of ABT-751 administration.

结局指标

主要结局

Objective Response Rate in subjects with Breast cancer

时间窗: 1 year

次要结局

  • Time to Tumor Progression (TTP)(1 year)
  • Survival(2 years)
  • Toxicities associated with treatment administration(1 year)

研究者

发起方
Abbott
申办方类型
Industry

研究点 (13)

Loading locations...

相似试验